Semaglutide

Semaglutide is a synthetic long-acting GLP-1 receptor agonist peptide derived from native human GLP-1(7-37), designed for selective activation of GLP-1R across pancreatic, gastrointestinal, central nervous and cardiovascular tissue. GLP-1 is a key incretin hormone mediating glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and hypothalamic satiety signaling, making semaglutide the most widely adopted single-target metabolic research peptide globally.

Laboratory researchers worldwide source Semaglutide 10mg lyophilized powder via Zypep Peptides Co., Limited official website zypep.com. Every production batch undergoes dual HPLC and mass spectrometry validation to confirm peptide identity and ≥99% purity, with downloadable Certificates of Analysis provided for institutional lab compliance, grant reporting and peer-reviewed study documentation. Strict endotoxin control ensures suitability for in-vitro cell culture and in-vivo rodent/primate preclinical models.

Semaglutide Structure and Design

Semaglutide’s 31-amino acid sequence is modified from native GLP-1 with targeted structural engineering to overcome rapid DPP-4 degradation and extend systemic circulation:

Unlike dual/triple incretin agonists (Tirzepatide, Retatrutide), semaglutide exhibits exclusive GLP-1 receptor selectivity, creating a critical control compound for comparative research isolating pure GLP-1 pathway effects independent of GIP or glucagon receptor modulation.

Chemical properties and registry information

Clinical data and research background

Semaglutide’s preclinical and clinical trial datasets form the foundational literature for modern GLP-1 peptide research, supported by the landmark SUSTAIN (glycemic control) and STEP (weight management) global Phase 3 trial series published across Diabetes Care, NEJM and Lancet Diabetes & Endocrinology journals.

STEP 1 landmark obesity trial (Wilding et al., NEJM 2021)

This 68-week randomized, placebo-controlled double-blind trial evaluated once-weekly semaglutide in adults with BMI ≥30 kg/m² without type 2 diabetes. At maximum maintenance dose, mean body weight reduction reached 16.9% from baseline, establishing the peptide’s robust single-target satiety and lipolytic activity for comparative metabolic laboratory research.

SUSTAIN clinical glycemia research program

The SUSTAIN trial series documented semaglutide’s dose-dependent HbA1c reduction, fasting glucose lowering and cardiovascular biomarker improvements in type 2 diabetic cohorts, generating standardized reference data for diabetes mechanism in-vitro and in-vivo research models.

Bulk research peptide supply

Zypep Peptides supplies factory-direct wholesale semaglutide lyophilized powder for university labs, biotech CROs and global peptide distributors. Contact our online inquiry support via the website chat box to request bulk volume discounts, batch test COA and worldwide door-to-door shipping quotations. All products labeled FOR LABORATORY RESEARCH USE ONLY, not formulated or authorized for human injection or oral administration.